Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm

Roland B. Walter,[1,2,3] Megan Othus,[4] Kaysey F. Orlowski,[1] Emily N. McDaniel,[1] Bart L. Scott,[1,5] Pamela S. Becker,[1,2] Mary-Elizabeth M. Percival,[1,2] Paul C. Hendrie,[2] Bruno C. Medeiros,[6] Michael T. Chiarella,[7] Arthur C. Louie[7] and Elihu H. Estey[1,2]

[1]Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; [2]Department of Medicine, Division of Hematology, University of Washington, Seattle, WA; [3]Department of Epidemiology, University of Washington, Seattle, WA; [4]Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA; [5]Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA and [6]Stanford University, CA; [7]Jazz Pharmaceuticals, Ewing, NJ, USA

Correspondence: rwalter@fredhutch.org
doi:10.3324/haematol.2017.182642

SUPPLEMENTAL TABLE. Cycle #1 treatment-emergent adverse events with CPX-351 at 32 units/m^2 or 64 units/m^2 per dose

Parameter	32 units/m^2 n (% cycles)	64 units/m^2 n (% cycles)
Fever, infection		
Bacteremia		
Catheter-related infection	2 (5.3%)	1 (10%)
Cellulitis		1 (10%)
Lung infection	3 (7.9%)	3 (30%)
Neutropenic fever	7 (18.4%)	5 (50%)
Sepsis	2 (5.3%)	1 (10%)
Cardiac		
Atrial tachycardia		1 (10%)
Cardiac arrest	1 (2.6%)	
Tachycardia		1 (10%)
Gastrointestinal		
Mucositis	2 (5.3%)	2 (20%)
General		
Multi-system organ failure		1 (10%)
Immune System		
Anaphylaxis		
Investigations		
Acute kidney injury	4 (10.5%)	2 (20%)
Alanine aminotransferase increase	1 (2.6%)	
Aspartate aminotransferase increase	1 (2.6%)	
Metabolism and nutritional		
Dehydration	1 (2.6%)	
Tumor lysis	1 (2.6%)	1 (10%)
Nervous system disorders		
Intracranial hemorrhage	1 (2.6%)	
Respiratory		
ARDS		1 (10%)
Atelectasis		1 (10%)
Bronchopulmonary hemorrhage	1 (2.6%)	
Hypoxia	3 (7.9%)	2 (20%)
Respiratory failure		1 (10%)
Other		
Deep vein thrombosis	1 (2.6%)	1 (10%)
Leg pain		1 (10%)
Urinary retention		1 (10%)

Table summarizing treatment-emergent grade 3-5 non-hematologic adverse effects that were experienced during treatment cycle #1 and were considered as definitively, probably, or possibly related to study treatment by the investigator.